Yahoo -> Finance -> Conversation
There are only 5 major mRNA companies on the market. Two that lead the sector, MRNA and BNTX, then there is CVAC, and then we have ARCT and TBIO. MRNA technology is going to revolutionize medicine, and this company is practically a small cap, so its potential upside is huge in the long term. The absence of catalysts may erode the price during this year, if this were the case, it would be an opportunity to buy (new or more). I think it cannot be ruled out that Sanofi will buy this company this year or next before it becomes very expensive. Sanofi paid $ 23 for its TBIO shares.
No comments:
Post a Comment